This study is testing if a drug called inclisiran can prevent major heart problems in people at high risk who haven’t had a major cardiovascular event before. Participants receive either inclisiran or a placebo through a shot on Day 1, Day 90, and every six months. The study aims to see if inclisiran can reduce the risk of cardiovascular death, heart attacks, strokes, and urgent heart procedures compared to a placebo.